Official Title

Prevention of Acute Pancreatitis After Endoscopic Interventions
  • Phase

    Phase 1
  • Study Type

    Interventional
  • Status

    Unknown status
  • Study Participants

    90
The aim of the study is to develop a method for the prevention of acute pancreatitis after minimally invasive interventions of the bile ducts using a drug regimen.
A prospective, randomized, single-center study is planned to identify the most effective drug regimen in order to prevent the development of acute pancreatitis after transpapillary interventions of the bile ducts.
Study Started
Aug 01
2020
Primary Completion
Jan 01
2021
Anticipated
Study Completion
Aug 01
2021
Anticipated
Last Update
Nov 18
2020

Drug Meksibel

2 ml solution

Meksibel Active Comparator

Intravenous 0.1 30 minutes before the procedure and 0.1 once a day for 3 days after the procedure

Indometacin Active Comparator

Into the rectum 1 hour before the procedure and 1 candle 1 time a day for 3 days after the procedure

Meloksicam Active Comparator

Intravenous 15 mg 30 minutes before the procedure and 15 mg once a day for 3 days after the procedure

Oktride Active Comparator

Intravenous 3 ml 30 minutes before the procedure and 3 ml once a day for 3 days after the procedure

Criteria

Inclusion Criteria:

Patients with cholangiolithiasis.
Patients with benign formations of the bile ducts.
Patients with malignant formations of the bile ducts.
Patients with extrahepatic bile duct cysts.
Patients with biliary hypertension of unknown etiology.
Patients with cholangitis.
Patients with extrahepatic bile duct strictures.
Patients suffering from oncopathology of the head of the pancreas, complicated by obstructive jaundice.
Patients with malignant pathology of the pancreas.
Patients with benign pancreatic pathology.

Exclusion Criteria:

ASA scale> III (severe concomitant cardiovascular pathology)
Severe pathology of the respiratory system.
Acute period of myocardial infarction.
Acute period of cerebral infarction.
No Results Posted